Brief: Cohbar Completes Enrollment In The Phase 1B Clinical Trial For Cb4211 Under Development For Nash And Obesity
29/03/2021 15:02
March 29 (Reuters) - CohBar Inc CWBR.O :
* COHBAR COMPLETES ENROLLMENT IN THE PHASE 1B CLINICAL TRIAL
FOR
CB4211 UNDER DEVELOPMENT FOR NASH AND OBESITY
* COHBAR INC - CURRENTLY EXPECTS TOPLINE DATA FROM PHASE 1B
STAGE
OF CB4211 CLINICAL STUDY AT END OF Q2
Source text for Eikon: ID:nGNX8PMhv3
Further company coverage: CWBR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CohBar
See all newsBrief: CohBar, Inc. Q2 EPS USD -1.49
Brief: Morphogenesis And CohBar Announce Positive Results From Phase 1B Trial Of IFX-HU2.0 Personalized Cancer Vaccine, In Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) And Cutaneous Squamous Cell Carcinoma (CSCC)
U.S. STOCKS ON THE MOVE-Galecto, Pinterest, Standard Lithium
CohBar surges on merger agreement with Morphogenesis
U.S. STOCKS ON THE MOVE-Chevron, Broadcom, Williams-Sonoma